JKE-1674

JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors[1][2][3].

Product Specifications

CAS Number

[2421119-60-8]

UNSPSC

12352005

Target

Ferroptosis; Glutathione Peroxidase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jke-1674.html

Concentration

10mM

Purity

99.54

Solubility

DMSO : 100 mg/mL (ultrasonic) |Ethanol : ≥ 50 mg/mL

Smiles

O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)/C(C[N+]([O-])=O)=N/O

Molecular Formula

C20H20Cl2N4O4

Molecular Weight

451.30

References & Citations

[1]Eaton JK, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16 (5) :497-506.|[2]Kathman SG, et al. A masked zinger to block GPX4. Nat Chem Biol. 2020;16 (5) :482-483.|[3]Viswanathan VS, et al. Unraveling Masked GPX4 Inhibitors. Nat. Chem. Biol. 2020, 16, 497–506.